Swedish Orphan Biovitrum AB (SOBIV)

241.30
+3.50(+1.47%)
  • Volume:
    284,792
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    238.00 - 241.40

SOBIV Overview

Prev. Close
237.8
Day's Range
238-241.4
Revenue
16.79B
Open
238.5
52 wk Range
166.5-245.4
EPS
8.52
Volume
284,792
Market Cap
71.36B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
643,469
P/E Ratio
25.76
Beta
0.398
1-Year Change
30.73%
Shares Outstanding
295,855,926
Next Earnings Date
Oct 27, 2022
What is your sentiment on Swedish Orphan Biovitrum?
or
Vote to see community's results!

Swedish Orphan Biovitrum AB News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Swedish Orphan Biovitrum AB Analysis

Swedish Orphan Biovitrum AB Company Profile

Swedish Orphan Biovitrum AB Company Profile

Employees
1532
Market
Sweden
  • Type:Equity
  • Market:Sweden
  • ISIN:SE0000872095
  • S/N:307114495

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy